

Issues with resistance and toxicity are reducing our ability to combat pests



70%

Up to 70% loss in stored Grain¹



26%

Of global crop production destroyed by insects²



50%

Of global population exposed to vector-borne diseases³



5

Classes of chemistry remaining with pressure to remove largest



586

Significant insect species now resistant to one or more insecticide class



>140k

Molecules must be screened to discover a potential new insecticide

What is the market looking for?

Bio-Gene has two unique compounds



Safe Chemistry

Low toxicity to bees & beneficial insects, no observable adverse effects to mammals



Efficacy

Compounds highly effective for controlling resistant pests across multiple verticals




A Novel Mode of Action

Compounds operate via a novel Mode of Action, addressing resistance to other classes of chemistry



Scalability

Production processes are refined, commercially viable



Qcide™

Natural Compound

Extract of an Australian eucalypt

Applications in:

- Consumer Products
- Public Health
- Crop Protection



Flavicide™

Nature Identical Compound

'Synthetic copy' of a natural compound that can be mass produced for broad verticals:

- Crop Protection
- Public Health

BGT's Novel Technology

BGT's technology is enabling a new generation of novel insecticides to address insect resistance

- Data shows BGT's products **Flavicide™** & **Qcide™** are highly effective in combatting resistant pests across:
 - 1) Crop Protection
 - 2) Grain Storage
 - 3) Public Health
 - 4) Consumer Products
- BGT's products operate via a novel Mode of Action

Total Addressable market of US\$25.1bn



Crop Protection



Grain Storage



Public Health



Consumer Products

Our proprietary chemistry represents a step-change for resistant pest control

BGT has a clear pathway to commercialisation

A	In-house Testing & Data Generation	Well Progressed
B	Progress Commercial Discussions Globally, via MTA's ⁴ and presenting Bio-Gene to various private and public organisations	Underway
C	Exclusive Partnership Trials, first signed with BASF for Grain Storage vertical	Announced
D	Progress partnerships to commercial deals	Future

Australian stored grain pest control partnership trial



Exclusive Grain Storage Partnership
Key representatives aligned & providing funding, market access, research, regulatory expertise & industry validation

Bio-Gene has a compelling value proposition



Data shows compounds are highly effective



Low toxicity to beneficial insects



>5,000x less impactful on bee populations



Novel Mode of Action



Strong IP portfolio



Scalable technology



Significant global opportunity across four verticals



Third-party validation of technology

Board & Management



Don Brumley
Non-Executive Chairman

- 25+ years as a senior partner & leader of Ernst & Young – Oceania
- Significant experience across IPOs, transactions, audit & advising growing entrepreneurial companies



Richard Jagger
CEO & Managing Director

- 20+ years working in agriculture globally
- Most recently employed as Managing Director of Sinochem Australia
- Previously spent 15+ years at Monsanto in various management roles



Peter May
Executive Director, R&D

- 20+ years experience in crop protection market with companies Orica & Crop Care Australasia (now Nufarm)
- Founded Xavca, consulted to companies such as Syngenta & Sorex (BASF)
- Former CEO & Chairman of BioProspect (now Medibio, ASX:MEB)



Robert Klupacs
Non-Executive Director

- 30+ years corporate experience in international tech development
- CEO of the Bionics Institute
- Previously MD & CEO of ASX-listed Circadian Technologies Ltd and ES Cell International Pte Ltd
- Registered Australian patent attorney



Kevin Rumble
Non-Executive Director

- Founding Director of Bio-Gene
- 20+ years experience in new plant propagation, farming & live plant transport techniques
- Involved in the development of Qcside™ & development of Flavesone as a first step in the commercialisation of Flavocide™



Roger Mcpherson
CFO & Company Secretary

- 15+ years experience as CFO & Company Secretary across both listed & unlisted companies
- Experience in the pharma manufacturing, biotech & biopharma industries
- Previously CFO & Co-Sec of TPI Enterprises (ASX:TPE)